SCHEMBL5873915

SCHEMBL5873915

O=C1Nc2ncc(-c3ccccc3)cc2/C1=C/Nc1ccc(I)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.43
KDR P35968 3/20 0.40
RPS6KA3 P51812 3/20 0.40
CDK8 P49336 3/20 0.40
CHEK1 O14757 2/20 0.40
PRKD3 O94806 2/20 0.40
MAP4K4 O95819 2/20 0.40
RET P07949 2/20 0.40
PIM1 P11309 2/20 0.40
FLT3 P36888 2/20 0.40
GSK3A P49840 2/20 0.40
GSK3B P49841 2/20 0.40
LIMK1 P53667 2/20 0.40
CDK5 Q00535 2/20 0.40
MAP4K2 Q12851 2/20 0.40
AURKB Q96GD4 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
NTRK1 P04629 2/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5873916 1.00 JAK3 (0.43) JAK3KDRRPS6KA3CDK8CHEK1
SCHEMBL5873979 0.85 CDK8 (0.37) JAK3KDRCDK8CHEK1MET
SCHEMBL5873978 0.85 CDK8 (0.37) JAK3KDRCDK8CHEK1MET
SCHEMBL5430362 0.85 ALDH1A1 (0.46) JAK3KDRRPS6KA3CDK8CHEK1
SCHEMBL5430358 0.85 ALDH1A1 (0.46) JAK3KDRRPS6KA3CDK8CHEK1
SCHEMBL5873783 0.84 RET (0.37) JAK3RPS6KA3RETPIM1NTRK1
SCHEMBL5873779 0.84 RET (0.37) JAK3RPS6KA3RETPIM1NTRK1
SCHEMBL5873773 0.82 NTRK1 (0.46) JAK3KDRRPS6KA3CDK8PRKD3
SCHEMBL5873771 0.82 NTRK1 (0.46) JAK3KDRRPS6KA3CDK8PRKD3
SCHEMBL5873796 0.82 JAK3 (0.39) JAK3KDRRPS6KA3CDK8CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
US-7129253-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-10-31 US disclosed
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US disclosed
US-20040191210-A1 Compounds GLENNON KIMBERLEY CAROLINE (US) 2004-09-30 US disclosed
US-6498176-B1 INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS SMITHKLINEBEECHAM CORPORATION 2002-12-24 US disclosed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US disclosed
US-6350747-B1 PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS GLAXO WELLCOME INC. 2002-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040191210-A1 Compounds CDK1, AKT1, RPS6KA1 JAK3 439/4885KDR 710/4885RPS6KA3 7/4885
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX JAK3 173/4885KDR 1225/4885RPS6KA3 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.